132 related articles for article (PubMed ID: 14614031)
41. Leukocytoclastic vasculitis due to thalidomide in multiple myeloma.
Yildirim ND; Ayer M; Küçükkaya RD; Alpay N; Mete O; Yenerel MN; Yavuz AS; Nalçaci M
Jpn J Clin Oncol; 2007 Sep; 37(9):704-7. PubMed ID: 17709605
[TBL] [Abstract][Full Text] [Related]
42. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.
Lokhorst HM; Schmidt-Wolf I; Sonneveld P; van der Holt B; Martin H; Barge R; Bertsch U; Schlenzka J; Bos GM; Croockewit S; Zweegman S; Breitkreutz I; Joosten P; Scheid C; van Marwijk-Kooy M; Salwender HJ; van Oers MH; Schaafsma R; Naumann R; Sinnige H; Blau I; Delforge M; de Weerdt O; Wijermans P; Wittebol S; Duersen U; Vellenga E; Goldschmidt H; ;
Haematologica; 2008 Jan; 93(1):124-7. PubMed ID: 18166796
[TBL] [Abstract][Full Text] [Related]
43. Thalidomide and lenalidomide in multiple myeloma.
Mazumder A; Jagannath S
Best Pract Res Clin Haematol; 2006; 19(4):769-80. PubMed ID: 16997182
[TBL] [Abstract][Full Text] [Related]
44. The effect of thalidomide on non-small cell lung cancer (NSCLC) cell lines: possible involvement in the PPARgamma pathway.
DeCicco KL; Tanaka T; Andreola F; De Luca LM
Carcinogenesis; 2004 Oct; 25(10):1805-12. PubMed ID: 15205358
[TBL] [Abstract][Full Text] [Related]
45. Thrombosis in multiple myeloma.
Zangari M; Elice F; Fink L; Tricot G
Expert Rev Anticancer Ther; 2007 Mar; 7(3):307-15. PubMed ID: 17338651
[TBL] [Abstract][Full Text] [Related]
46. A multicenter phase II trial of thalidomide and celecoxib for patients with relapsed and refractory multiple myeloma.
Prince HM; Mileshkin L; Roberts A; Ganju V; Underhill C; Catalano J; Bell R; Seymour JF; Westerman D; Simmons PJ; Lillie K; Milner AD; Iulio JD; Zeldis JB; Ramsay R
Clin Cancer Res; 2005 Aug; 11(15):5504-14. PubMed ID: 16061867
[TBL] [Abstract][Full Text] [Related]
47. [Therapeutic outcomes in systemic lymphatic diseases and plasmacytoma. New hope for palliative patients].
Heinrich B
MMW Fortschr Med; 2005 Jun; 147(24):23. PubMed ID: 16001528
[No Abstract] [Full Text] [Related]
48. A low serum level of soluble tumor necrosis factor receptor p55 predicts response to thalidomide in advanced multiple myeloma.
Brenne AT; Romstad LH; Gimsing P; Juliusson G; Turesson I; Romundstad P; Borset M; Sundan A; Waage A
Haematologica; 2004 May; 89(5):552-6. PubMed ID: 15136218
[TBL] [Abstract][Full Text] [Related]
49. Individualizing treatment of patients with myeloma in the era of novel agents.
San-Miguel J; Harousseau JL; Joshua D; Anderson KC
J Clin Oncol; 2008 Jun; 26(16):2761-6. PubMed ID: 18427148
[TBL] [Abstract][Full Text] [Related]
50. Thalidomide as a targeted therapy for multiple myeloma.
Dan K
Intern Med; 2003 Jul; 42(7):550-1. PubMed ID: 12879943
[No Abstract] [Full Text] [Related]
51. [An old drug as a carcinostatic. The new career of thalidomide].
Holzgrabe U
Pharm Unserer Zeit; 2007; 36(6):446-9. PubMed ID: 17957689
[TBL] [Abstract][Full Text] [Related]
52. Thalidomide is effective for extramedullary relapse of multiple myeloma post-allogeneic bone marrow transplantation.
Biagi JJ; Prince HM
Br J Haematol; 2001 Nov; 115(2):484-5. PubMed ID: 11703354
[No Abstract] [Full Text] [Related]
53. The revitalization of thalidomide.
Thomas DA; Kantarjian HM
Ann Oncol; 2001 Jul; 12(7):885-6. PubMed ID: 11521791
[No Abstract] [Full Text] [Related]
54. Treatment of multiple myeloma: an emphasis on new developments.
Kyle RA; Vincent Rajkumar S
Ann Med; 2006; 38(2):111-5. PubMed ID: 16581696
[TBL] [Abstract][Full Text] [Related]
55. Modification of thrombomodulin plasma levels in refractory myeloma patients during treatment with thalidomide and dexamethasone.
Corso A; Lorenzi A; Terulla V; Airò F; Varettoni M; Mangiacavalli S; Zappasodi P; Rusconi C; Lazzarino M
Ann Hematol; 2004 Sep; 83(9):588-91. PubMed ID: 15235749
[TBL] [Abstract][Full Text] [Related]
56. Thalidomide for the treatment of multiple myeloma.
Hattori Y; Iguchi T
Congenit Anom (Kyoto); 2004 Sep; 44(3):125-36. PubMed ID: 15327481
[TBL] [Abstract][Full Text] [Related]
57. [Thalidomide treatment of patients with refractory myeloma in the institutes participating in the Japan Myeloma Study Group].
Murakami H; Handa H; Imai K; Kanakura Y; Kosaka M; Sawamura M; Shimazaki C; Suzuki K; Ishii A; Takagi T; Taniwaki M; Togawa A; Hata H; Wakayama T; Takatsuki K;
Rinsho Ketsueki; 2004 Jun; 45(6):468-72. PubMed ID: 15287523
[TBL] [Abstract][Full Text] [Related]
58. Second response to lower-dose thalidomide in a patient with multiple myeloma.
Lee FC
Blood; 2002 Jun; 99(11):4248; author reply 4249. PubMed ID: 12043696
[No Abstract] [Full Text] [Related]
59. Role of thalidomide in previously untreated patients with multiple myeloma.
Musto P; D'Auria F; Pietrantuono G; Bringhen S; Morabito F; Di Raimondo F; Pozzi S; Sacchi S; Boccadoro M; Palumbo A; ;
Expert Rev Anticancer Ther; 2008 Oct; 8(10):1569-80. PubMed ID: 18925849
[TBL] [Abstract][Full Text] [Related]
60. Thalidomide: tragic past and promising future.
Rajkumar SV
Mayo Clin Proc; 2004 Jul; 79(7):899-903. PubMed ID: 15244387
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
